Literature DB >> 18815862

Facioscapulohumeral dystrophy: case report and discussion.

Vincenzo Castellano1, Joseph Feinberg, Jennifer Michaels.   

Abstract

Facioscapulohumeral dystrophy (FSHD) is often cited as the third most common form of muscular dystrophy. Therefore, it should be considered in patients with complaints of progressive weakness. We present the case of a man with facial, truncal, and leg weakness that initially sought medical attention for lower back pain. Electrodiagnostic testing revealed findings in the trapezius, serratus anterior, biceps, triceps, pectoralis major, tibialis anterior, and gastrocnemius muscles consistent with a myopathic disorder. Subsequent genetic testing identified a FSHD allele size consistent with a FSHD deletion mutation. Therefore, confirming the diagnosis of FSHD. Unfortunately, no effective treatments currently exist for FSHD. However, supportive measures involving physical therapy and the use of orthotics may aid in improving function and mobility.

Entities:  

Year:  2008        PMID: 18815862      PMCID: PMC2553176          DOI: 10.1007/s11420-008-9078-3

Source DB:  PubMed          Journal:  HSS J        ISSN: 1556-3316


  19 in total

Review 1.  Facioscapulohumeral dystrophy.

Authors:  J T Kissel
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

2.  Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients.

Authors:  J-T Vilquin; J-P Marolleau; S Sacconi; I Garcin; M-N Lacassagne; I Robert; B Ternaux; B Bouazza; J Larghero; C Desnuelle
Journal:  Gene Ther       Date:  2005-11       Impact factor: 5.250

3.  Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy.

Authors:  R J Osborne; S Welle; S L Venance; C A Thornton; R Tawil
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

4.  Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy.

Authors:  Patrick Reed; Neil C Porter; John Strong; David W Pumplin; Andrea M Corse; Paul W Luther; Kevin M Flanigan; Robert J Bloch
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

5.  Sensitivity of motor unit potential analysis in facioscapulohumeral muscular dystrophy.

Authors:  Simon Podnar; Janez Zidar
Journal:  Muscle Nerve       Date:  2006-10       Impact factor: 3.217

Review 6.  Facioscapulohumeral muscular dystrophy.

Authors:  Rabi Tawil; Silvère M Van Der Maarel
Journal:  Muscle Nerve       Date:  2006-07       Impact factor: 3.217

7.  Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy.

Authors:  J E Hewitt; R Lyle; L N Clark; E M Valleley; T J Wright; C Wijmenga; J C van Deutekom; F Francis; P T Sharpe; M Hofker
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

8.  Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy.

Authors:  David B Olsen; Mette Cathrine Ørngreen; John Vissing
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

9.  Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies.

Authors:  Roberta Morosetti; Massimiliano Mirabella; Carla Gliubizzi; Aldobrando Broccolini; Cristina Sancricca; Mario Pescatori; Teresa Gidaro; Giorgio Tasca; Roberto Frusciante; Pietro Attilio Tonali; Giulio Cossu; Enzo Ricci
Journal:  Stem Cells       Date:  2007-08-30       Impact factor: 6.277

10.  Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy.

Authors:  D D Kilmer; R T Abresch; M A McCrory; G T Carter; W M Fowler; E R Johnson; C M McDonald
Journal:  Am J Phys Med Rehabil       Date:  1995 Sep-Oct       Impact factor: 2.159

View more
  1 in total

1.  Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice.

Authors:  Sachchida N Pandey; Jennifer Cabotage; Rongye Shi; Manjusha Dixit; Margret Sutherland; Jian Liu; Stephanie Muger; Scott Q Harper; Kanneboyina Nagaraju; Yi-Wen Chen
Journal:  Biol Open       Date:  2012-05-25       Impact factor: 2.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.